Imbruvica - direct healthcare professional communication (DHPC)

Ibrutinib

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events

Dissemination date: 03/11/2022

Key facts

• Medicine name:
  Imbruvica
• Active substance:
  Ibrutinib
• Therapeutic area (MeSH):
  • Lymphoma, Mantle-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
• Procedure number:
  EMEA/H/C/003791/II/0075
• Regulatory outcome:
  Variation
• DHPC type:
  Post-authorisation measure
• Human ATC codes:
  L01EL01
• Dissemination date:
  03/11/2022